overal growth profil deserv premium stick
post in-line organ growth improv sequenti
neotract roll-in off-set higher spend urolift pipelin
telegraph guidanc call adj ep midpoint
in-line upsid potenti pipelin sell-off surpris
consid signific gain exit prior lrp solid setup rais
outer year pt
organ growth jump urolift inclus guid look conserv
organ growth improv last primarili roll-in neotract
 base busi although estim partial stub
comparison addit month ad growth base busi
also improv sequenti volum contribut last new product
last price last look ahead initi
organ growth guid look conserv acceler urolift contribut
pipelin consid outlook call minim benefit
manta percuv contribut repla among see
urolift best posit deliv upsid momentum recent aua guidelin
inclus dtc advertis new rep better reimburs versu competit
margin soft telegraph spend new cost-out program cushion lrp target
adj om fell short expect actual spend urolift
pipelin acceler off-set lower tax ad although
trajectori margin gain non-linear overal result signific
bp sinc lrp plan versu target furthermor step-back
margin spend support urolift manta replaswhich pois
drive consist return oper still nearli increment cost
save harvest restructur inclus new plan
current tax cap structur drive annual ep
tweak rais pt still confid time
revis goe prior revis
goe prior reflect higher urolift contribut
off-set higher spend dtc launch effort japan manta urolift
look like substanti bend growth profil higher year
come signific room margin expans strong balanc sheet solid track
record deal make see share pois upsid look ahead
combin support outlook ep support
upsid case time
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
buy thesi predic best-in-class report
organ top-lin growth profil rel peer
continu upsid adjust om restructur
balanc sheet flexibl support continu tuck-in
posit one better posit
mid-cap hospit suppli provid compani
increasingli attract larger diversifi med-tech peer
deep-div analysi neotract acquisit doc survey
along detail bottom-up analysi restructur
success bla trial clearanc repla
launch percuv manta
aua meet may
msd organ growth annual om
contribut urolift
limit market releas launch percuv manta
repla launch
follow-on deal similar scale neotract near-term
base case pt use revis forecast
hsd organ growth annual om expans
contribut urolift
higher contribut percuv manta
repla
follow-on deal similar scale neotract near-term
bull case pt use bull-cas ep
lsd organ growth annual om expans
sub contribut urolift
deceler growth increas competit
delay market releas percuv manta repla
follow-on deal similar scale neotract rise debt
bear case pt use bear-cas ep
pleas see import disclosur inform page report
gener earn estim reflect cash ep calcul
financi summari market data
gener earn estim reflect cash ep calcul
estim valuat
pleas see import disclosur inform page report
urolift anoth strong ahead launch japan
propel ul overtim
urolift grew contribut last growth
acceler come primarili new physician add increas
vs despit signific growth acceler outlook
urolift robust remaind current lrp plan due
continu low penetration/util us eventu launch japan us
compani initi target activ bph surgeon eventu urologist
suggest high user penetr littl total penetr
hover around averag util still case per month
versu averag total bph surgeri per month activ account dispers
remain wide new surgeon averag high user approach case
per month earli shonin clearanc japan also substanti opportun given
urologist region estim local per year contribut
expect kick-in follow receipt nation reimburs expect next
month take us traction japan total compani highli
confid hit target
pleas see import disclosur inform page report
